新一代近红外金属小分子光敏药物开发/Small Molecular Drugs for Near-Infrared-Triggered PDT - ebet

ebet,ebet官网

新闻动态 | 党群建设 | 联系我们
ebet / / 新一代近红外金属小分子光敏药物开发/Small Molecular Drugs for Near-Infrared-Triggered PDT
新一代近红外金属小分子光敏药物开发/Small Molecular Drugs for Near-Infrared-Triggered PDT

       光动力疗法(Photodynamic Therapy, PDT)是结合光和光敏药物治疗肿瘤和皮肤性病的新方法,具有创伤小、选择性好、适用范围广、非侵入性等特点。

       ?激发波长处于最佳“生物光学窗口”(700-850 nm), 组织穿透深度可达到10 mm左右,高反应活性

       ?原创生物正交技术,有效提高药物靶向性,为精准治疗提供可能性

       ?原位检测治疗过程: 影像介入光动力治疗

     本项目开发系列具有高光敏活性、宽近红外窗口、高穿透深度的光敏剂原型药物,解决光敏剂在光动力治疗临床应用中的光敏活性、穿透深度、靶向性等关键技术难点。 

        Photodynamic Therapy (PDT) is a new treatment of tumor and skin diseases by combining light and photosensitizing drugs,which features small trauma (even non-invasiveness), good selectivity and wide application range.

        ?Excitation wavelength at "bio-optical window" (700-850 nm), the tissue penetration depth up to 10 mm, and high PDT reactivity

        ?Original bio-orthogonal technology: improve drug targeting and potential for precise treatment

         ?In situ monitoring the treatment process combing imaging and PDT

        We aim to develop a series of prototypes of photosensitizers with high photosensitivity, wide near-infrared window and high penetration depth, which are perspective to overcome the key issues of photosensitizers occurring in clinical PDT applications.